INS and type 2 diabetes mellitus: The treat-to-target trial BEGIN Once Long30 compared treatment with IDeg-100 and Gla-100 in insulin-naive individuals with type 2 diabetes and revealed similar glycemic control and overall rates of confirmed hypoglycemia for IDeg and Gla-100, and fewer episodes of nocturnal confirmed hypoglycemia with IDeg.